Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials

By Karasik Avraham   Aschner Pablo   Katzeff Harvey   Davies Michael J.   Stein Peter P.  

Current Medical Research and Opinion, Vol. 24, Iss. 2, 2008-02 ,pp. : 489-496

Informa Healthcare

Access to resources Recommend Favorite

Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes

By Pratley Richard E.   Salsali Afshin  

Current Medical Research and Opinion, Vol. 23, Iss. 4, 2007-04 ,pp. : 919-931

Informa Healthcare

Access to resources Recommend Favorite

Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes

By Hanefeld Markolf   Herman Gary A.   Wu Mei   Mickel Carolyn   Sanchez Matilde   Stein Peter P.    

Current Medical Research and Opinion, Vol. 23, Iss. 6, 2007-06 ,pp. : 1329-1339

Informa Healthcare

Access to resources Recommend Favorite

Non‐inferiority of silodosin 4 mg once daily to twice daily for storage symptoms score evaluated by the International Prostate Symptom Score in Japanese patients with benign prostatic hyperplasia: A multicenter, randomized, parallel‐group study

By  

INTERNATIONAL JOURNAL OF UROLOGY, Vol. 22, Iss. 3, 2015-03 ,pp. : 311-316

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 20, Iss. 2, 2018-02 ,pp. : 378-388

John Wiley & Sons Inc

Access to resources Recommend Favorite